Mucosal Biomarker of Innate Immune Activation Predicts Response to Vedolizumab in Crohn's Disease.
Osterman MT, Gordon IO, Davis EM, Ciorba M, Glover SC, Abraham B, Khan F, Guo X, Yee EU, Allard FD, Claggett B, Shen B, Liu JJ.
Osterman MT, et al. Among authors: claggett b.
Inflamm Bowel Dis. 2020 Sep 18;26(10):1554-1561. doi: 10.1093/ibd/izz222.
Inflamm Bowel Dis. 2020.
PMID: 31553433